Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...

Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) Between October 2019 and June 2021, 32 patients with dMMR/MSI-H gastric/GEJ adenocarcinoma were enrolled. The median age was 65 ...

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial Median age of treated ...

Opdivo® (nivolumab) in combination with Yervoy® (ipilimumab) has been made available within NHS Scotland for the first line treatment of adult patients with mismatch repair deficient (dMMR) or ...

Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...

Sixteen patients with mismatch repair–deficient, locally advanced rectal cancer were enrolled in a pilot study in which 6 months of neoadjuvant anti–PD-1 therapy was to be followed by surgical ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...